Biological markers in body fluids for activity and progression in multiple sclerosis

Area of Science:

• Neuroimmunology
• Biomarker Discovery
• Multiple Sclerosis Pathophysiology

Background:

• Accurate biomarkers in body fluids are crucial for understanding multiple sclerosis (MS) pathophysiology and guiding therapeutic decisions.
• Current challenges include the localized nature of central nervous system inflammation versus systemic immune markers.
• Existing research shows promise for markers like adhesion molecules, cytokines, co-stimulatory molecules, and neopterin in relapsing-remitting MS.

Purpose of the Study:

• To evaluate the reliability of body fluid biomarkers for monitoring multiple sclerosis (MS) disease activity and progression.
• To assess the potential of specific molecules as indicators of disease status in individual MS patients.

Main Methods:

• Review of studies investigating adhesion molecules, pro-inflammatory cytokines, co-stimulatory molecules, and neopterin.
• Analysis of biomarker correlation with disease activity in various multiple sclerosis subtypes.
• Assessment of marker utility for individual patient monitoring.

Main Results:

• Studies indicate promising results for certain biomarkers in groups of patients with relapsing-remitting multiple sclerosis.
• However, these markers do not consistently correlate with disease activity at the individual patient level.
• No single body fluid marker currently demonstrates sufficient correlation for individual MS monitoring.

Conclusions:

• Existing body fluid biomarkers are insufficient for precise monitoring of individual multiple sclerosis disease activity, progression, or therapeutic response.
• Further research is needed to identify more reliable biomarkers for personalized MS management.
• The localized CNS immune response in MS poses a significant challenge for systemic biomarker detection.